# Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)

> **NCT02038933** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 121 (actual)

## Conditions studied

- Lymphoma. Non-Hodgkin

## Interventions

- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02038933
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-05
- **Primary completion:** 2016-04-08
- **Final completion:** 2020-10-08
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2021-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02038933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02038933, "Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02038933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*